ClinicalTrials.gg
CompletedNCT01291173BEDUpdated Jun 10, 2021Results posted

Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder

A Phase 2 interventional study of lisdexamfetamine dimesylate (SPD489) and lisdexamfetamine dimesylate (SPD489) in Binge Eating Disorder, sponsored by Shire. Completed at 31 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
13th of 112
271 · median 67
Started
2011
the only one that year
Phase 2
14 of 122
1 open now
Registered
26th of 122
by date
Lead sponsor
5 of 122
Shire

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 13th largest by enrollment of the 112 interventional ones that give a count, is the only one that started in 2011, is one of 14 in phase 2, and was the 26th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of SPD489 compared to placebo in the treatment of moderate to severe binge eating disorder as measured by the number of binge days per week

03

Conditions studied

  • Binge Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject meets the following Fourth Edition - Text Revision (DSM-IV-TR) criteria for a diagnosis of binge eating disorder (BED).
  • Binge eating disorder is of at least moderate severity in which subjects report at least 3 binge eating days per week.
  • Subject has a (BMI) of >24 and \<46.

Exclusion criteria

Exclusion

  • Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
  • Subject is considered a suicide risk or risk to harm others.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    SPD489 30 mg

    Drug: lisdexamfetamine dimesylate (SPD489)

  • Experimental
    SPD489 50 mg

    Drug: lisdexamfetamine dimesylate (SPD489)

  • Experimental
    SPD489 70 mg

    Drug: lisdexamfetamine dimesylate (SPD489)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Log Transformed Binge Days Per Week at Week 11

    Binge day is defined as a day during which at least 1 binge episode occurs.

    Time frame: Baseline and week 11

Secondary outcomes

  1. Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks

    The number of binge episodes per week as assessed by clinical interview based on subject diary.

    Time frame: Baseline and up to 11 weeks

  2. 1-Week Binge Response, Last Observation Carried Forward (LOCF)

    The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline \[ie, a cessation of binge eating behavior\]), or a marked response (75 to \<100% reduction in binge episodes from baseline), or a moderate response (50 to \<75% reduction in binge episodes from baseline), or a negative/minimal response (\<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.

    Time frame: Last 7 days on study

  3. 4-Week Binge Response

    Subjects are free from binge episodes for 4 weeks.

    Time frame: Last 28 days on study

  4. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Baseline

  5. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: up to 11 weeks

  6. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 11 weeks

  7. Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11

    The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.

    Time frame: Baseline and week 11

  8. Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11

    MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

    Time frame: Baseline and week 11

  9. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11

    The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.

    Time frame: Baseline and week 11

  10. Change From Baseline in Eating Inventory Score at Week 11

    The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.

    Time frame: Baseline and week 11

  11. Change From Baseline in Binge Eating Scale (BES) Score at Week 11

    The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.

    Time frame: Baseline and week 11

  12. Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11

    The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.

    Time frame: Baseline and week 11

  13. Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11

    The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).

    Time frame: Baseline and week 11

07

Results

Posted Dec 31, 2012
Limitations and caveats
External investigation at a site was initiated for reasons unrelated to the study. Lacking information on the investigation, it was deemed prudent to exclude data from subjects enrolled at site (n=11) from the primary analyses of efficacy and safety.

Participant flow

Participant flow — Overall Study
MilestonePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Started64666565
Completed47515252
Not completed17151313
Withdrew: Adverse event0313
Withdrew: Protocol violation7225
Withdrew: Withdrawal by subject6442
Withdrew: Lost to follow-up4632
Withdrew: Unable to meet visit schedule0010
Withdrew: Lack of compliance0001
Withdrew: Subject was unblinded0010
Withdrew: Excluded therapy0010

Outcome measures

PrimaryChange From Baseline in Log Transformed Binge Days Per Week at Week 11

Binge day is defined as a day during which at least 1 binge episode occurs.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · Log days
Change From Baseline in Log Transformed Binge Days Per Week at Week 11
Log daysPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Log Transformed Binge Days Per Week at Week 11-1.23 ± 0.069-1.24 ± 0.067-1.49 ± 0.066-1.57 ± 0.067
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.8825 · Mean difference (final values): -0.014 · 95% CI -0.203 to 0.175
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.0077 · Mean difference (final values): -0.258 · 95% CI -0.446 to -0.069
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.0004 · Mean difference (final values): -0.345 · 95% CI -0.534 to -0.155
SecondaryChange From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks

The number of binge episodes per week as assessed by clinical interview based on subject diary.

Time frame:
Baseline and up to 11 weeks
Reported as:
Mean · Binge Episodes
Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks
Binge EpisodesPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in the Number of Binge Episodes Per Week at Up to 11 Weeks-4.07 ± 2.718-4.57 ± 3.266-5.10 ± 3.026-5.09 ± 2.586
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Cochran-Mantel-Haenszel · p = 0.4676
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Cochran-Mantel-Haenszel · p = 0.0198
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Cochran-Mantel-Haenszel · p = 0.0031
Secondary1-Week Binge Response, Last Observation Carried Forward (LOCF)

The 1-week binge response was defined as either a 1-week remission (a 100% reduction of binge episodes from baseline \[ie, a cessation of binge eating behavior\]), or a marked response (75 to \<100% reduction in binge episodes from baseline), or a moderate response (50 to \<75% reduction in binge episodes from baseline), or a negative/minimal response (\<50% reduction in binge episodes from baseline). The 1-week response was determined at the end of the study utilizing a LOCF approach.

Time frame:
Last 7 days on study
Reported as:
Number · Participants
1-Week Binge Response, Last Observation Carried Forward (LOCF)
ParticipantsPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
1 week remission23283335
Marked response15202423
Moderate response13841
Negative/Minimal response111034
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Cochran-Mantel-Haenszel · p = 0.3341
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Cochran-Mantel-Haenszel · p = 0.0063
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Cochran-Mantel-Haenszel · p = 0.0022
Secondary4-Week Binge Response

Subjects are free from binge episodes for 4 weeks.

Time frame:
Last 28 days on study
Reported as:
Number · Participants
4-Week Binge Response
ParticipantsPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
4-Week Binge Response13222731
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Cochran-Mantel-Haenszel · p = 0.0937
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Cochran-Mantel-Haenszel · p = 0.0127
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Cochran-Mantel-Haenszel · p = 0.0009
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Baseline
Reported as:
Number · Percentage of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline
Percentage of participantsPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Normal, not at all ill0000
Borderline mentally ill0001.6
Mildly ill1.603.11.6
Moderately ill56.554.559.442.9
Markedly ill29.030.329.747.6
Severely ill11.312.16.36.3
Among the most extremely ill1.63.01.60
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
up to 11 weeks
Reported as:
Number · Percentage of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Up to 11 Weeks
Percentage of participantsPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Normal, not at all ill37.155.460.965.1
Borderline mentally ill19.426.223.420.6
Mildly ill12.91.56.311.1
Moderately ill24.213.87.83.2
Markedly ill6.51.51.60
Severely ill0000
Among the most extremely ill01.500
SecondaryPercentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 11 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks
Percentage of participantsPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Up to 11 Weeks64.584.690.693.7
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Chi-squared · p = 0.0091
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Chi-squared · p = 0.0004
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Chi-squared · p = <0.0001
SecondaryChange From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11

The YBOCS-BE measures the obsession of binge-eating thoughts and compulsiveness of binge-eating behaviors. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). Total scores range from 0 to 40. A score of 0-7 is sub-clinical; 8-15 is mild; 16-23 is moderate; 24-31 is severe; and 32-40 is extreme.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (YBOCS-BE) Total Score at Week 11-12.0 ± 0.87-15.0 ± 0.84-15.3 ± 0.83-17.0 ± 0.83
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.0142 · Mean difference (final values): -2.97 · 95% CI -5.34 to -0.60
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.0075 · Mean difference (final values): -3.25 · 95% CI -5.62 to -0.88
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -4.93 · 95% CI -7.30 to -2.56
SecondaryChange From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Score at Week 11-1.7 ± 0.35-1.9 ± 0.34-1.3 ± 0.33-1.6 ± 0.33
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.7538 · Mean difference (final values): -0.15 · 95% CI -1.11 to 0.80
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.3062 · Mean difference (final values): 0.49 · 95% CI -0.45 to 1.44
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.7697 · Mean difference (final values): 0.14 · 95% CI -0.81 to 1.09
SecondaryChange From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11

The HAM-A is a rating scale developed to quantify the severity of anxiety symptomatology. It consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe) with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity, and 25-30 moderate to severe, and 31-56 severe anxiety.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Score at Week 11-1.5 ± 0.30-0.9 ± 0.29-1.1 ± 0.29-0.6 ± 0.29
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.2046 · Mean difference (final values): 0.53 · 95% CI -0.29 to 1.35
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.3348 · Mean difference (final values): 0.40 · 95% CI -0.42 to 1.22
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.0505 · Mean difference (final values): 0.81 · 95% CI -0.00 to 1.63
SecondaryChange From Baseline in Eating Inventory Score at Week 11

The Eating Inventory also known as the Three-Factor Eating Questionnaire is a 51-item self-reported questionnaire intended to assess 3 dimensions of eating behavior: cognitive restraint of eating, disinhibition, and hunger. Cognitive restraint of eating consists of 20 items, disinhibition consists of 16 items, and hunger consists of 15 items. Each item scores either 0 or 1 point for a total score of 0-20 for cognitive restraint of eating, 0-16 for disinhibition, and 0-15 for hunger. A higher score is better for cognitive restraint of eating and lower scores are better for disinhibition and hunger.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Eating Inventory Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Cognitive restraint of eating2.5 ± 0.654.4 ± 0.623.8 ± 0.614.3 ± 0.62
Disinhibition-3.8 ± 0.58-5.6 ± 0.56-6.3 ± 0.55-7.2 ± 0.56
Hunger-3.3 ± 0.58-5.3 ± 0.56-6.0 ± 0.55-7.8 ± 0.56
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.0371
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.1380
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.0459
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.0278
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.0022
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = <0.0001
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.0149
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.0009
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = <0.0001
SecondaryChange From Baseline in Binge Eating Scale (BES) Score at Week 11

The BES is a 16-item self-reported questionnaire that is designed to assess behavioral, affective, and attitudinal components of the subjective experience of binge eating. The items are summed, with possible scores ranging from 0 to 46. A score of 27 or higher indicates severe binge-eating problems, and a score of 17 or lower designates no binge-eating problems.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Binge Eating Scale (BES) Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Binge Eating Scale (BES) Score at Week 11-12.2 ± 1.28-16.1 ± 1.25-17.6 ± 1.24-20.6 ± 1.24
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.030 · Mean difference (final values): -3.9 · 95% CI -7.44 to -0.38
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -5.4 · 95% CI -8.95 to -1.94
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -8.5 · 95% CI -11.99 to -4.92
SecondaryChange From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11

The BIS-11 is a self-reported 30-item questionnaire that measures impulsiveness using a 4-point Likert scale (rarely/never = 1, occasionally = 2, often = 3, almost always/always = 4). A Total Impulsivity score is calculated by summing the scores for each item. Possible scores range from 30 - 120. Higher scores indicate increased impulsiveness.

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Change From Baseline in Barratt Impulsiveness Scale (BIS-11) Total Score at Week 11-3.1 ± 1.09-5.8 ± 1.05-5.2 ± 1.05-6.9 ± 1.05
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.0824 · Mean difference (final values): -2.65 · 95% CI -5.64 to 0.34
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.1725 · Mean difference (final values): -2.07 · 95% CI -5.05 to 0.91
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.0148 · Mean difference (final values): -3.71 · 95% CI -6.69 to -0.73
SecondaryChange From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11

The SF-12 is a 12-item self-report questionnaire that is a subset of the SF-36 Health Survey. The survey captures physical and mental health. There are 8 subscales. Four of the subscales has one-item each; the other 4 have two-items each. For each subscale, a mean value was first computed and transformed to a position on a scale ranging from 0-100 (Z-transformation). The aggregate total scores are then transformed into a mean value ranging from 0 (lowest level of health) to 100 (highest level of health).

Time frame:
Baseline and week 11
Reported as:
Least squares mean · units on a scale
Change From Baseline in Short Form-12 Health Survey (SF-12) Score at Week 11
units on a scalePlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Aggregate Physical Score1.3 ± 0.782.6 ± 0.752.4 ± 0.743.9 ± 0.75
Aggregate Mental Score4.9 ± 1.035.0 ± 1.005.5 ± 0.994.9 ± 1.00
Statistical analysis
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.2504 · Mean difference (final values): 1.25 · 95% CI -0.89 to 3.38
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.3090 · Mean difference (final values): 1.09 · 95% CI -1.02 to 3.21
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.0216 · Mean difference (final values): 2.50 · 95% CI 0.37 to 4.64
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 30 mg · Mixed Models Analysis · p = 0.9587 · Mean difference (final values): 0.07 · 95% CI -2.75 to 2.90
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 50 mg · Mixed Models Analysis · p = 0.6530 · Mean difference (final values): 0.64 · 95% CI -2.17 to 3.45
  • Placebo vs Lisdexamfetamine Dimesylate (SPD489) 70 mg · Mixed Models Analysis · p = 0.9814 · Mean difference (final values): 0.03 · 95% CI -2.79 to 2.86

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/63 (0%)37/63 (58.7%)
Lisdexamfetamine Dimesylate (SPD489) 30 mg—2/66 (3%)57/66 (86.4%)
Lisdexamfetamine Dimesylate (SPD489) 50 mg—0/65 (0%)56/65 (86.2%)
Lisdexamfetamine Dimesylate (SPD489) 70 mg—1/65 (1.5%)53/65 (81.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Drug toxicityInjury, poisoning and procedural complications0/630/660/651/65
Pancreatitis acuteGastrointestinal disorders0/631/660/650/65
AppendicitisInfections and infestations0/631/660/650/65
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mg
Dry mouthGastrointestinal disorders5/6322/6622/6527/65
Decreased appetiteMetabolism and nutrition disorders4/6317/6613/6512/65
InsomniaPsychiatric disorders1/637/6610/659/65
HeadacheNervous system disorders6/639/669/655/65
NasopharyngitisInfections and infestations2/638/661/653/65
NauseaGastrointestinal disorders0/635/666/654/65
Weight decreasedInvestigations1/632/664/656/65
ConstipationGastrointestinal disorders1/636/663/655/65
DiarrheaGastrointestinal disorders0/634/665/651/65
Feeling jitteryGeneral disorders0/631/663/655/65

Baseline characteristics

Safety Analysis Set defined as all randomized subjects who had taken at least 1 dose of investigational product and who had at least 1 follow-up safety assessment completed. One subject in the Placebo group did not have a post-baseline safety assessment and was excluded from the safety population (n=259).

Age, Continuous
Age, Continuous(years)PlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mgTotal
Mean38.0 ± 10.3038.4 ± 11.1439.6 ± 9.3238.6 ± 10.0138.7 ± 10.17
Age, Customized
Age, Customized(Participants)PlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mgTotal
18-39 years35353034134
40-55 years28313531125
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mgTotal
Female49575055211
Male149151048
Region of Enrollment
Region of Enrollment(Participants)PlaceboLisdexamfetamine Dimesylate (SPD489) 30 mgLisdexamfetamine Dimesylate (SPD489) 50 mgLisdexamfetamine Dimesylate (SPD489) 70 mgTotal
United States63666565259
08

Study locations

31 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Southwestern Research, Inc.
    Beverly Hills, California 90210, United States
  • Scripps Clinical Research Services
    La Jolla, California 92037, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • Florida Clinical Research
    Bradenton, Florida 32408, United States
  • Gulfcoast Clinical Research
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Atlanta Institute of Medicine and Research
    Atlanta, Georgia 30328, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Vince and Assoc. Research
    Overland Park, Kansas 66212, United States
  • Clinical Trials Technology, Inc.
    Prairie Village, Kansas 66206, United States
  • Louisiana Research Associates, Inc.
    New Orleans, Louisiana 70114, United States
  • Marc Hertzman, MD, PC
    Rockville, Maryland 20852, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02135, United States
  • Unniversity of Minnesota
    Minneapolis, Minnesota 55454, United States
  • Weight Disorders Washington University School of Medicine, Dept of Psychiatry
    Saint Louis, Missouri 63110, United States
  • Robert Lynn Horne, MD
    Las Vegas, Nevada 89102, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Neuropsychiatric Research Institute
    Fargo, North Dakota 58103, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Lindner City of Hope
    Mason, Ohio 45040, United States
  • Weight Management Center, Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Clinical Trials
    Austin, Texas 78731, United States
  • Drug Development, Inc.
    Houston, Texas 77081, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
09

References and documents

Publications

  • McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015 Mar;72(3):235-46. doi: 10.1001/jamapsychiatry.2014.2162. PubMed 25587645 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2011 to primary completion in Jan 2012, 8 months.

Results were first posted in Dec 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2011
First posted
Feb 8, 2011
StartActual
May 10, 2011
Primary completionActual
Jan 30, 2012
CompletionActual
Jan 30, 2012
Results first posted
Dec 31, 2012
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01291173
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Feb 8, 2011
Start date
May 10, 2011
Primary completion
Jan 30, 2012
Completion
Jan 30, 2012
Results posted
Dec 31, 2012
Last update
Jun 10, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion